Can CF drugs tame diabetes in cystic fibrosis?

NCT ID NCT07102043

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study looks at whether CFTR modulators (ETI) help control blood sugar in people with cystic fibrosis-related diabetes (CFRD). Researchers will compare 30 adults with CFRD who take ETI to those who cannot take it. The goal is to see if the drug improves how the body handles sugar after meals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CFTR modulator (elexacaftor/tezacaftor/ivacaftor, ETI)
What this could lead to: If successful, this could clarify whether CFTR modulators improve blood sugar regulation in cystic fibrosis-related diabetes, pointing toward better management strategies.
What could go wrong: This is a small observational study (30 people) measuring metabolic markers, not clinical outcomes. It may not prove direct benefit or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS RELATED DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis-related diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS RELATED DIABETES

Contacts and locations

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 352294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.